Rapport Therapeutics (NASDAQ:RAPP) Trading 6% Higher

Rapport Therapeutics (NASDAQ:RAPP)’s stock price rose 6% on Tuesday . The company traded as high as $25.72 and last traded at $25.72. Approximately 51,660 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 249,428 shares. The stock had previously closed at $24.27.

Wall Street Analyst Weigh In

RAPP has been the topic of several recent research reports. Jefferies Financial Group began coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price target on the stock. Finally, TD Cowen began coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a “buy” rating for the company.

Rapport Therapeutics Stock Performance

Insider Transactions at Rapport Therapeutics

In other news, Director James Healy bought 44,032 shares of the stock in a transaction on Monday, July 1st. The shares were bought at an average price of $24.52 per share, with a total value of $1,079,664.64. Following the completion of the acquisition, the director now owns 40,851 shares of the company’s stock, valued at $1,001,666.52. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.